Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg twice daily (b.d.). This report gives the results of a detailed pharmacokinetic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, M., MacNeill, F., Mehta, A., Newton, C., Haynes, B., Jones, A., Jarman, M., Lonning, P., Powles, T. J., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977449/
https://www.ncbi.nlm.nih.gov/pubmed/1931611

Ejemplares similares

Ejemplares similares